May 29, 2018 – Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early vessel healing in its target patient population at one month following implantation of the Resolute Onyx drug-eluting stent (DES). The target population contained a high percentage of patients with complex coronary artery disease.
Presented at the EuroPCR Annual Meeting, May 22-25 in Paris, France, data from 15 patients – including 13 with acute coronary syndrome (ACS) – were evaluated using optical coherence tomography (OCT). OCT is a light-based intracoronary imaging modality that provides extremely high-quality images of the coronary wall, especially of the structures closest to the vessel lumen.
In the Onyx 1-Month OCT Study, patients implanted with the Resolute Onyx DES demonstrated an excellent early healing profile. Results showed an average of 88 percent of struts covered by neointimal formation (new cell growth over stent struts) and 92.3 percent of the total stented area showing complete strut coverage at one month, which includes the covered areas in between the struts.
“The signal of early healing is crucial for patients who may need to interrupt or discontinue dual antiplatelet therapy (DAPT) within a short period of time after receiving a stent,” said Elvin Kedhi, M.D., Ph.D., interventional cardiologist at Isala Hartcentrum in Zwolle, the Netherlands, one of the lead principal investigators of the Onyx 1-Month OCT Study. “These data help expand the growing body of clinical evidence that may support physicians in tailoring DAPT regimens for complex patients.”
The Onyx 1-Month OCT Study is the latest of several Medtronic-funded studies helping to generate additional clinical evidence to reinforce the understanding of healing and shorter DAPT regimens in complex patients. Last year, Medtronic announced the Onyx ONE Global Study, a randomized clinical trial that will compare one-month DAPT between two DES for the first time, which is currently enrolling. A similar study will launch in the U.S. and Japan later this calendar year and will help inform DAPT guidelines for newer-generation DES that currently favor bare-metal stents (BMS) for patients at an increased risk of bleeding who might require a shorter DAPT regimen.
In a separate analysis presented at the EuroPCR meeting, new data from the DAPT-STEMI trial in patients treated with the Resolute Integrity DES, showed excellent results in a prospective prespecified registry that evaluated all patients after six months of DAPT duration, prior to randomization. At six months, the patient-oriented composite primary endpoint (all-cause mortality, any myocardial infarction [MI], any revascularization, stroke and TIMI major bleeding [net NACCE]) occurred in 4.2 percent of patients, with low rates of target lesion revascularization (1.1 percent) and stent thrombosis (0.7 percent).
The Resolute Onyx DES with thinner struts features Core Wire Technology, an evolution of Continuous Sinusoid Technology (CST). CST is a unique Medtronic method of stent manufacturing, which involves forming a single strand of cobalt alloy wire into a sinusoidal wave to construct a stent. This enables greater deliverability and conformability to the vessel wall. With Core Wire Technology, a radiopaque inner core is incorporated within the cobalt alloy wire to enhance visibility for accurate stent placement. Core Wire Technology also enables thinner struts while maintaining structural strength.
The Resolute Onyx DES received CE (Conformité Européene) Mark in September 2014 and U.S. Food and Drug Administration (FDA) approval in April 2017.
For more information: www.medtronic.com